CanaQuest Medical Corp.
Award-winning, Clinical Stage/Life-Sciences company focused on the drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain receptors. The company is targeting anxiety, depression, and PTSD, including addiction. The Company is the industry partner for research and product development with Dr. Steven Laviolette, a professor and neuroscientist with over 20 years of experience in the field of mental health and cannabinoids at Western University. Dr. Laviolette and his team of 13 scientists made two amazing discoveries that are Drug Candidates targeting neurological conditions: Drug Candidate for epilepsy, CQ-001, is supported by (cannabidiol “CBD” + IP formula) - molecules bond and synergistically attach to PPAR receptors allowing CQ-001 to cross the blood-brain barrier (BBB) to target the central nervous system (the brain) with amplified effects and efficacy. CBD by itself did not do this in the pre-clinical trials.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Globally (various continents)
- Year Founded:
- 2008
- Employees:
- 1-10
- Turnover:
- less than $1,000,000 US
About Us
Novel Formulation Bases and Pre-clinical Trial Results for Rx Drug Candidates
CanaQuest Medical is a clinical-stage life sciences company focused on the drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain receptors.
CanaQuest is collaborating with multiple Canadian universities including a Western University team led by Dr. Steven Laviolette, who has decades of research experience focused on novel pharmacotherapies to treat neurological conditions, such as anxiety, depression, schizophrenia, and Post Traumatic Stress Disorder “PTSD”, including addiction.
Dr. Laviolette’s team has made two amazing drug candidate discoveries, Rx CQ-001 (CBD molecules + formula) and Rx CQ-002 (THC molecules + formula), for treating mental ailments. Pre-clinical trials completed – setting the stage for pre-approved clinical trials.
To learn more about our value proposition and our pre-approved clinical trials, view our Corporate Presentation by clicking the thumbnail graphic further down.
2022 Global Excellence Awards
Best Medical Cannabis and Botanical Oils Product Development Company, 2022 – North America
Awarded by Global Health & Pharma, UK
Game Changing Formulations - IP Protected, International Patents Filed
- Drug candidate, CQ-001, supported by (cannabidiol “CBD” + IP formula) – molecules bond and synergistically attach to PPAR receptors allowing CQ-001 to cross the blood-brain barrier (BBB) to target the central nervous system (the brain) with amplified effects and efficacy.
CBD by itself did not do this in the pre-clinical trials.
Pre-clinical trial results – published in peer-reviewed European Journal of Neuroscience. Oct. 2020.
- Drug candidate, CQ-002, supported by (cannabinoid “THC” + IP formula) – is a safer alternative to all other THC products. Pre-clinical trials demonstrated reversal of depression-like and schizophrenia related symptoms, complete blockage of memory impairment, hyperactive activity, and gene vulnerability.
Pre-clinical trial results – published in peer-reviewed European Journal of Neuroscience Oct. 2020 & International Journal of Molecular Sciences July 2021.
The Company intends to incorporate Artificial Intelligence (AI) to help diagnose and evaluate mental health at the beginning and through the medication period. By including advanced machine learning algorithms, novel formulation methods, and well-established industry approaches, we are driving the evolution of the mental health industry to improve the lives of millions globally.
CanaQuest has research and clinical trial collaborations with multiple Canadian universities and Institutions and has identified the regulatory pathways for CQ-001 to obtain Rx Drug Identification Numbers (DINs) in the USA and Canada for Epilepsy rare neurological conditions, projected ∼ 3 years.
Western University
Pre-clinical trials completed for CQ-001 and CQ-002
Dr. Laviolette is a scientific veteran with 20 years of research experience in the field of mental health and cannabinoids and he oversees a dedicated team of 13 scientists, with a focus on neuropsychiatric disorders like anxiety, depression, post-traumatic stress disorder (PTSD), and Addiction.
University of Montreal
Q2 2022 – initiating pre-approved clinical trial (Phase II, randomized, triple-blind crossover feasibility study) for efficacy and dosage of our cannabinoid based formulated drug-candidates, CQ-001 and CQ-002, for the treatment of Cannabis Use Disorder “CUD”.
McMaster University
Q3 2022 – initiating clinical trial (Phase II, double-blind feasibility trial, 30 patients) to further refine efficacy and dosage of CQ-001 for humans.
Ontario Brain Institute
Q2 2022 – EpLink, the Epilepsy Research Program funded by the Ontario Brain Institute, is conducting a study using rodent models to establish dosing requirements for CQ-001. These results will set the stage for clinical trials to treat refractory epileptic syndromes (high efficacy, less dosage, reduced negative side effects).
Q4 2022 – study results will define dosage of CQ-001 for clinical trial (Phase II/III, double-blind trial, 60 patients) and will facilitate a submission to Health Canada and subsequently, the US-FDA for a new drug.
Hydrx Farms
Q3 2022 – our Contract Manufacturer, GMP and clinical trial compliance, is completing the SOPs for the Clinical Trial Application process required for the approved and funded clinical trial at the University of Montreal (Cannabis Use Disorder – efficacy, dosage, and safety, 24 patients), for evaluating CanaQuest’s CQ-001 and CQ-002 drug candidates.
Pre-approved and Pending Clinical Trials
The Company is primed to realize the infinite potential of targeted therapeutics within the endocannabinoid system and specific brain receptors to mediated signaling pathways.
CanaQuest has won Best Medical Cannabis and Botanical Oils Product Development Company, 2022 – North America………awarded by Global Health & Pharma, UK.
Focus Areas
- Anxiety
- Addiction
- Depression
- Schizophrenia
- PTSD
- Chronic Pain
Our Vision
Our vision is to be a global leader in the formulation and development of medicine derived from cannabinoids and other botanical-based molecules.
Business Strategy
Company Direction
CanaQuest is focused on the drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain receptors. The Company intends to treat neurological conditions, such as anxiety, depression, schizophrenia, epilepsy, and Post Traumatic Stress Disorder “PTSD”, including addiction.
CanaQuest’s mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies.
Strategy
CanaQuest’s strategy is to:
- Continue developing scientific-backed proprietary formulations with its scientific partners, backed by pre-clinical trial results.
- Conduct clinical trials for drug candidates with universities and institutions (pre-approved & funded, and pending clinical trials)
- Partner with a global pharmaceutical organization.
CanaQuest has research and clinical trial collaborations with multiple Canadian universities, including a Western University team led by Dr. Steven Laviolette, a neuroscientist, who has decades of research and pre-clinical trial experience, focused on novel cannabinoid and botanical pharmacotherapies, addressing neurological conditions
The Company has brought together a wealth of management, commercialization, research & development, clinical trial, and regulatory expertise. As well, advanced manufacturing and pharmaceutical marketing/sales capabilities are in place.
CanaQuest is leveraging its multidisciplinary expertise by strengthening its Board of Directors and inviting Physicians, Psychiatrists, Healthcare Practitioners and regulatory professionals to join its Medical Advisory Board.
Advisor Shared Values and Expertise:- Shared passion to make a real difference in quality of life
- Scientific knowledge and expertise in cannabinoid-based medicine
- Currently or amenable to prescribing cannabinoids.
The Company is following the same regulatory pathway that GW Pharma took to obtain approvals for Epidiolex to treat Dravet & Lennox Gastaut Syndromes, rare neurological conditions under the umbrella of epilepsy.
Regulatory pathways are mapped out for RX CQ-001 to obtain Rx Drug Identification Numbers (DINs) in the USA and Canada for Epilepsy rare neurological conditions, with projected approvals in about 3 years.
Pre-clinical trials have been completed by Western University for Rx CQ-001 & Rx CQ-002.
Drug candidate, Rx CQ-001, supported by (CBD molecules + formula) – molecules bond and synergistically attach to PPAR receptor allowing Rx CQ-001 to cross the blood-brain barrier (BBB) to target the central nervous system (the brain) with amplified effects and efficacy. CBD by itself does not do this.
Epidiolex Formula is 99% CBD – sesame as carrier oil (non-active)
Pre-Approved and Pending Clinical Trials are as Follows:
University of Montreal
Q2 2022 – initiating pre-approved clinical trial (Phase II, randomized, triple-blind crossover feasibility study) for efficacy and dosage of our cannabinoid based formulated drug-candidates, Rx CQ-001 and Rx CQ-002, for the treatment of Cannabis Use Disorder “CUD”. https://labo-jutras-aswad.ca/en/laboratory/
McMaster University
Ontario Brain Institute
Ontario Brain Institute
Q1 2022 – EpLink https://eplink.ca/, the Epilepsy Research Program funded by the Ontario Brain Institute, will conduct a study using rodent models to establish dosing requirements for Rx CQ-001. These results will set the stage for clinical trials to treat refractory epileptic syndromes (high efficacy, less dosage, reduced negative side effects).
Q4 2022 – study results will define dosage of Rx CQ-001 for clinical trial (Phase II/III, double-blind trial, 60 patients) and will facilitate a submission to Health Canada and subsequently, the US-FDA for a new drug.
Partners
The Company’s business model is to develop formulated drug candidates, backed by science, and pre-clinical & clinical trials for medicinal purposes. CanaQuest is looking to partner with a manufacturer that has global pharmaceutical production capabilities, expertise, including distribution networks. This model enables the Company to process and distribute anywhere in the world, subject to being compliant with the respective country’s regulations.
Working with Dr. Steve Laviolette, a professor and neuroscientist, at Western University, who has over 20 years of research experience in the field of mental health and cannabinoids and who oversees a team of 13 scientists, gives CanaQuest a tremendous competitive advantage. Successful pre-clinical trial results have set the stage for human trials in pursuit of pharmaceutical drugs. Clinical Trial opportunities are significant as several cannabinoid researchers, in the Canadian university sector, have fully funded grants awarded to undertake cannabinoid research including clinical trials.
The Company has identified the Rx regulatory pathway for a Pharma drug candidate, targeting neurological conditions – initiating Human Clinical Trials. It is following the FDA regulatory pathway developed by Jazz Pharmaceuticals (formerly GW Pharma) for the approval of Epidiolex.
Drug Candidate Formulations
CanaQuest is primed to realize the infinite potential of targeted therapeutics within the endocannabinoid system and specific brain receptors to mediated signaling pathways.
CQ-001, Drug Candidate – Epilepsy (CBD molecules + formula)
Clinical-trial stage
Supports anxiety, depression, schizophrenia, PTSD and addiction
CQ-002, Drug Candidate – Safer alternative (THC molecules + formula)
Clinical-trial stage
Supports mental health: safer alternative to THC by itself
CQ-003, Drug Candidate – Pain (CBD molecules + formula)
In development
To support inflammation & pain
CQ-004, Drug Candidate – Alzheimer’s (THC + CBD molecules + formula)
In development
To support mental health
Technology
The problem is that Mental Disorders are on the rise and there is limited science behind “medical” cannabinoid products.
- Global cost – mental disorders will cost the global economy $16 trillion by 20301
- Mental health ailments – 1 in 5 North Americans has some type of mental health condition2,3,4
- Limited science-backed cannabinoid natural plant solutions – to treat mental Illnesses (alternative to opioids)
- Cannabinoid medicine – physicians have a difficult time prescribing precise doses
- Neurological treatment limitations – cannabidiol (CBD) by itself does not effectively cross the blood-brain barrier
- Only one CBD pharmaceutical drug on the market – approved by the US-FDA – to treat epileptic neurological conditions – Epidiolex®, developed by former GW Pharma
CanaQuest has a solution.
Game Changing Formulations – IP protected, International Patents Filed
- Drug candidate, Rx CQ-001, supported by (CBD molecules + formula) – molecules bond and synergistically attach to PPAR receptor allowing Rx CQ-001 to cross the blood-brain barrier (BBB) to target the central nervous system (the brain) with amplified effects and efficacy. CBD by itself does not do this.
Pre-clinical trial results – published in peer-reviewed European Journal of Neuroscience. Oct. 2020.
- Drug candidate, Rx CQ-002, supported by (THC molecules + formula) – is a safer alternative to all other THC products. Pre-clinical trials demonstrated reversal of depression-like and schizophrenia related symptoms, complete blockage of memory impairment, hyperactive activity, and gene vulnerability.
Pre-clinical trial results – published in peer-reviewed European Journal of Neuroscience Oct. 2020 & International Journal of Molecular Sciences July 2021.
1) Psychiatric Times, November 2018
2) Open Minds, May 13, 2020
3) Mental Health Commission of Canada
4) National Alliance on Mental Illness (NAMI)
Strategy
- Continue developing scientific-backed proprietary formulations with its scientific partners, backed by pre-clinical trial results.
- Conduct clinical trials for drug candidates with universities and institutions (pre-approved & funded, and pending clinical trials)
- Partner with a global pharmaceutical organization.
- University of Montreal (Phase II)………pre-approved and funded
- McMaster University (Phase II)…………pre-approved and funded
- Ontario Brain Institute (Phase II/III)….clinical study funded & a pending clinical trial
Sustainability
Sustainability is a crucial consideration for all businesses, whether they realize it or not.
CanaQuest Medical Corp has made a concerted effort to create drug candidates that put the health of the world at its core.
By utilizing cannabinoid molecules and other botanical molecules, combined with university collaboration, we create drug candidates that will contribute to a healthier and happier planet.
Social Responsibility
CanaQuest Medical Corp is committed to upholding and respecting Canadian values and human rights in all of our business dealings. For us, this commitment means that we strive to govern ourselves according to a spirit of fairness and environmental awareness.
Environment
At its core, CanaQuest Medical Corp is an environmental company. By supplanting carbon-intensive alternatives to our products (such as high-protein meats, marine based Omega-3, and others), we are helping to turn the tide on climate change. As CanaQuest grows, we will continue to find ways to minimize our environmental impact.
Discrimination
As a global company, CanaQuest Medical Corp embraces diversity and respects differences in cultures, religions, and socio-economic statuses. We are aware of the damage that workplace discrimination can do to people and emerging economies. We are also aware that discrimination does not make business sense for us or our clients. For these reasons, CabaQuest views skill, qualifications, and experience as the basis of recruitment. In our dealings with other entities, we will not enter into contracts that contain any discriminatory workplace clauses, nor will we contemplate working with entities that have discriminatory policies.
Further, we commit ourselves to being aware of formal structures and informal cultural issues that can prevent employees from raising concerns and grievances, and will work to bypass these.
Human Rights
CanaQuest Medical Corp will not work with companies or individuals suspected of committing human rights abuses, or where we feel that our participation in a project may endanger human rights. Where we have concerns, we will review ongoing relationships and encourage clients to continue to observe human rights in all situations.
Bribery & Corruption
CanaQuest Medical Corp has a zero tolerance towards bribery and corruption, and is committed to acting professionally, ethically, and fairly in its business dealings and relationships. This means that we will neither accept nor offer a bribe under any circumstance. Further, we will not partner with any entity that engages in bribery. Companies with which we do business may be confident that CanaQuest Medical Corp is committed to fairness in the market.
